These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 29946373

  • 1. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C.
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [Abstract] [Full Text] [Related]

  • 2. Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
    Roulois D, Blanquart C, Panterne C, Gueugnon F, Grégoire M, Fonteneau JF.
    Eur J Immunol; 2012 Mar; 42(3):783-9. PubMed ID: 22144115
    [Abstract] [Full Text] [Related]

  • 3. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
    Leclercq S, Gueugnon F, Boutin B, Guillot F, Blanquart C, Rogel A, Padieu M, Pouliquen D, Fonteneau JF, Grégoire M.
    Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
    [Abstract] [Full Text] [Related]

  • 4. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S.
    Epigenetics; 2015 Nov; 10(5):431-45. PubMed ID: 25923331
    [Abstract] [Full Text] [Related]

  • 5. The role of epigenetics in malignant pleural mesothelioma.
    Vandermeers F, Neelature Sriramareddy S, Costa C, Hubaux R, Cosse JP, Willems L.
    Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
    [Abstract] [Full Text] [Related]

  • 6. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
    Wu Y, Sang M, Liu F, Zhang J, Li W, Li Z, Gu L, Zheng Y, Li J, Shan B.
    Carcinogenesis; 2020 Jul 14; 41(7):894-903. PubMed ID: 32529260
    [Abstract] [Full Text] [Related]

  • 7. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A.
    Oncol Rep; 2014 Dec 14; 32(6):2365-72. PubMed ID: 25231602
    [Abstract] [Full Text] [Related]

  • 8. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 9. Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
    Hamaidia M, Staumont B, Duysinx B, Louis R, Willems L.
    Curr Top Med Chem; 2016 May 01; 16(7):777-87. PubMed ID: 26303419
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 May 01; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, Jablons DM, You L.
    J Cell Mol Med; 2018 Jun 01; 22(6):3139-3148. PubMed ID: 29575535
    [Abstract] [Full Text] [Related]

  • 18. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May 01; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

  • 19. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
    Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, Saito K, Wakabayashi T.
    J Neurooncol; 2009 Mar 01; 92(1):15-22. PubMed ID: 19030781
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.